Glickman Mark A — SEC Form 4 filings
SEC reporting owner CIK 1441461. 4 Form 4 filings on record with FilingPulse; latest filed 2026-08-28.
Transaction summary — filings shown
Covers all 4 filings on record, filed 2024-06-07 to 2026-08-28. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 5.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| MetaVia Inc. (MTVA) | Director | 3 | — | — | 3 |
| BioStem Technologies, Inc. (BSEM) | Director | 1 | — | — | 2 |
Form 4 filings — Glickman Mark A
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-28 | 4 | BioStem Technologies, Inc. (BSEM) | Option exercise (M): 7,671 @ $0 · Option exercise (M): 7,671 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | MetaVia Inc. (MTVA) | Grant/award (A): 17,186 @ $0 | EDGAR |
| 2025-07-01 | 4 | MetaVia Inc. (MTVA) | Grant/award (A): 28,147 @ $0 | EDGAR |
| 2024-06-07 | 4 | NeuroBo Pharmaceuticals, Inc. (NRBO) | Grant/award (A): 5,051 @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1441461 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →